Literature DB >> 21242869

Postoperative cervical myelopathy and cord compression associated with the use of recombinant bone morphogenetic protein-2 in posterior cervical decompression, instrumentation, and arthrodesis: a report of two cases.

David W Anderson1, Douglas C Burton, R Sean Jackson.   

Abstract

STUDY
DESIGN: Case report.
OBJECTIVE: Two cases are presented in which the use of recombinant bone morphogenetic protein-2 (rh-BMP-2) in a posterior cervical decompression and instrumented arthrodesis may have contributed to seroma formation and cord compression. SUMMARY OF BACKGROUND DATA: The use of rh-BMP-2 has been proven effective in promoting bone formation in anterior lumbar spine arthrodesis. Whether rh-BMP-2 is safe and/or effective in the cervical spine has not been determined. Adverse effects when it is used for anterior cervical fusion procedures have been reported but its role in posterior cervical decompression and instrumented fusions has yet to be determined.
METHODS: We report on two cases. The first is a 68-year-old man presenting with a substantial decline in his neurologic status approximately 2 weeks after surgery. The second is a 44-year-old man presenting with a substantial decline in his neurologic status approximately 5 days after surgery. Both complications occurred after a posterior cervical laminectomy and instrumented arthrodesis when rh-BMP-2 was used as a bone graft substitute.
RESULTS: Both patients were found to have a moderate-to-large seroma causing severe compression on the spinal cord and were urgently taken to an operating room for evacuation of the seromas. Both showed improvement of their neurologic status immediately after surgery. As rh-BMP-2 is known to occasionally cause seroma formation it is postulated that it may have been the cause of the seromas.
CONCLUSION: Caution should be exercised with rh-BMP-2 use in posterior cervical applications when a laminectomy has been performed. The safe and effective dose and technique for application have yet to be determined. Seroma formation is possible, which can cause acute stenosis with cord compression and neurologic compromise.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21242869     DOI: 10.1097/BRS.0b013e3181f8f4d3

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  8 in total

Review 1.  A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2.

Authors:  Aaron W James; Gregory LaChaud; Jia Shen; Greg Asatrian; Vi Nguyen; Xinli Zhang; Kang Ting; Chia Soo
Journal:  Tissue Eng Part B Rev       Date:  2016-04-19       Impact factor: 6.389

2.  Posterior cord syndrome associated with postoperative seroma: The case to perform a complete neurologic exam.

Authors:  Meghan Cochrane; Marika Hess; Natalie Sajkowicz
Journal:  J Spinal Cord Med       Date:  2018-12-14       Impact factor: 1.985

3.  Suicide gene approach using a dual-expression lentiviral vector to enhance the safety of ex vivo gene therapy for bone repair.

Authors:  F Alaee; O Sugiyama; M S Virk; H Tang; H Drissi; A C Lichtler; J R Lieberman
Journal:  Gene Ther       Date:  2013-11-28       Impact factor: 5.250

4.  Bone morphogenetic protein in complex cervical spine surgery: A safe biologic adjunct?

Authors:  Darren R Lebl
Journal:  World J Orthop       Date:  2013-04-18

5.  Intradiscal injection of simvastatin results in radiologic, histologic, and genetic evidence of disc regeneration in a rat model of degenerative disc disease.

Authors:  Khoi D Than; Shayan U Rahman; Lin Wang; Adam Khan; Kwaku A Kyere; Tracey T Than; Yoshinari Miyata; Yoon-Shin Park; Frank La Marca; Hyungjin M Kim; Huina Zhang; Paul Park; Chia-Ying Lin
Journal:  Spine J       Date:  2013-12-01       Impact factor: 4.166

6.  Acute Intravenous Injection Toxicity Study of Escherichia coli-Derived Recombinant Human Bone Morphogenetic Protein-2 in Rat.

Authors:  Jae Hyup Lee; Eui-Nam Lee; Bong-Soon Chang; Choon-Ki Lee
Journal:  Asian Spine J       Date:  2014-04-08

7.  Role of bone morphogenetic protein-2/4 in astrocyte activation in neuropathic pain.

Authors:  Lin Yang; Shuxin Liu; Yaping Wang
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

8.  Use of Allogenic Mesenchymal Cellular Bone Matrix in Anterior and Posterior Cervical Spinal Fusion: A Case Series of 21 Patients.

Authors:  Srikanth Naga Divi; Mark M Mikhael
Journal:  Asian Spine J       Date:  2017-06-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.